Last reviewed 2026-04-20 · How we verify

Leuprolide Open Label (leuprolide-open-label)

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Neutropenia
• Nausea
• Fatigue
• Diarrhoea
• Hot flush
• Arthralgia
• Asthenia
• Vomiting
• Alopecia
• Constipation
• Neutrophil count decreased
• Anaemia

Key clinical trials

• Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (PHASE2, PHASE3)
• A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer (PHASE3)
• Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients (PHASE2)
• A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (PHASE2)
• A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer (PHASE1)
• Safety and Efficacy Evaluation of LC-K76 in Patients With Metastatic Hormone-Sensitive Prostate Cancer (EARLY_PHASE1)
• Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer (PHASE2)
• Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (EARLY_PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.